Xvivo Perfusion AB (CHIX:XVIVOS) Moat Score : 5/10 (As of Jun. 27, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Xvivo Perfusion AB Moat Score?

Xvivo Perfusion AB has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Xvivo Perfusion AB has Narrow Moat: Xvivo Perfusion AB has a solid narrow moat due to its valuable intellectual property and patents in the medical field. The company benefits from regulatory barriers and a strong distribution network, but lacks significant market leadership and pricing power to be considered a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Xvivo Perfusion AB might have Narrow Moat - Solid narrow moat.

Competitive Comparison of Xvivo Perfusion AB's Moat Score

For the Medical Devices subindustry, Xvivo Perfusion AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xvivo Perfusion AB's Moat Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Moat Score falls into.

Save Embed

;

Save Embed

;

Xvivo Perfusion AB (CHIX:XVIVOs) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score	Moat Level
10	Wide Moat - Exceptionally dominant and durable wide moat
8 - 9	Wide Moat - Clear and robust wide moat
7	Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6	Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5	Narrow Moat - Solid narrow moat
4	Narrow Moat - Discernible but modest moat
1 - 3	No Moat - Very weak/transient advantages
0	No Moat - No discernible moat

Xvivo Perfusion AB Moat Score Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Moat Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (CHIX:XVIVOs) » Definitions » Moat Score

Comparable Companies

Traded in Other Exchanges

XVIPF:USA XVIVO:Sweden 0RKL:UK 3XV:Germany

Address

Gemenskapens gata 9, Molndal, SWE, SE-431 53

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines